Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease , today. | March 24, 2022
Cardiol Therapeutics Inc is commercializing its THC-free cannabidiol formulation to treat heart disease proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Proprietary formulation produces ultra-pure pharmaceutical cannabidiol (CBD) without the psychotropic effects of THC for the treatment of inflammatory heart disease
Received US FDA approval to commence a Phase II/III COVID-19 trial investigating the cardioprotective properties of CardiolRx
Has launched Cortalex through a national agreement with Medical Cannabis by Shoppers to retail it on an exclusive basis across Canada
Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease.
The Canadian specialty pharmaceutical company has developed a proprietary formula of ultra-pure pharmaceutical cannabidiol (CBD) that does not contain THC - less than 5 parts per million (ppm) - and consequently none of the psychotropic effects of THC.
Cardiol Therapeutics Inc.: Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.